Staphylococcus epidermidis DnaK alters biofilm formation and proteome in Staphylococcus aureus CIP 107093
Frontiers in Microbiology · 18.02.2026 · 16
DOI: 10.3389/fmicb.2025.1705130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 18.02.2026. Verfasst von Clara Kayser und 13 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit Bacterial Communication and Anti-infectious Strategies (CBSA, UR4312), University of Rouen Normandie, Evreux, France. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Staphylococcus aureus and Staphylococcus epidermidis , two Gram-positive bacteria of the human skin microbiota, form biofilms that contribute to dysbiosis and inflammatory skin diseases such as psoriasis and atopic dermatitis. The human calcitonin gene-related peptide (CGRP), involved in skin inflammation, was previously shown to enhance the virulence of S. epidermidis MFP04. We previously observed a significant increase in the level of the molecular chaperone DnaK/Hsp70 in the secretome of CGRP-activated S. epidermidis . Here, we investigated the role of recombinant S. epidermidis DnaK in biofilm formation in both S. aureus and S. epidermidis . DnaK modulates biofilm formation in a strain-dependent manner. In commensal strains ( S. aureus MFP03 and S. epidermidis MFP04), it is associated with an increase in biofilm biomass. In contrast, it significantly reduces biofilm formation in the clinical S. aureus strain CIP 107093. Point mutations in the substrate-binding domain (SBD) and nucleotide-binding domain (NBD) of DnaK differentially affect its modulation of biofilm formation. Specifically, only the mutation in the SBD abolishes the biofilm reduction observed in CIP 107093, while the NBD mutation results in a milder effect. Notably, these mutations have no significant impact on DnaK-induced biofilm changes in strains where DnaK promotes biofilm formation. Proteomic analyses of S. aureus CIP 107093 reveal that DnaK alters the S. aureus biofilm proteome, stabilizing protein degradation components and downregulating key biofilm regulators. These findings highlight the cross-species regulatory potential of S. epidermidis extracellular DnaK in the skin microbiota.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Unit Bacterial Communication and Anti-infectious Strategies (CBSA, UR4312), University of Rouen Normandie, Evreux, France.
- Paris Cité, CNRS USR2000, Unité de Spectrométrie de Masse pour la Biologie, Plateforme de protéomique, Paris, France.
- Centre de Biochimie Structurale, CNRS UMR 5048-INSERM 1054, University of Montpellier, Montpellier, France.
- NanoTemper Technologies GmbH, Munich, Germany.
- Institut Pasteur, Université Paris Cité, Collection of Institut Pasteur (CIP), Paris, France.
Zitieren
APA
Kayser, C., Druart, K., Bouscasse, E., Matondo, M., Chane, A., Hoh, F., Groboillot, A., Barbey, C., Merieau, A., Latour, X., Soule, P., Mühle, E., Norris, V., & Konto-Ghiorghi, Y. (2026). Staphylococcus epidermidis DnaK alters biofilm formation and proteome in Staphylococcus aureus CIP 107093. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1705130
Vancouver
Kayser C, Druart K, Bouscasse E, Matondo M, Chane A, Hoh F, et al. Staphylococcus epidermidis DnaK alters biofilm formation and proteome in Staphylococcus aureus CIP 107093. Frontiers in Microbiology. 2026;16. doi:10.3389/fmicb.2025.1705130
BibTeX
@article{Kayser2026,
author = {Kayser, Clara and Druart, Karen and Bouscasse, Eleonore and Matondo, Mariette and Chane, Andréa and Hoh, François and Groboillot, Anne and Barbey, Corinne and Merieau, Annabelle and Latour, Xavier and Soule, Pierre and Mühle, Estelle and Norris, Vic and Konto-Ghiorghi, Yoan},
title = {Staphylococcus epidermidis DnaK alters biofilm formation and proteome in Staphylococcus aureus CIP 107093},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fmicb.2025.1705130}
}
EUVIMED